METASTATIC SOLID TUMOR

This early-stage study tests a new drug called IL12-L19L19 in people with advanced or spreading solid tumors that no longer respond to standard immunotherapy. The main goal is to find a safe dose and check for early signs that the drug shrinks tumors. About 80 adults aged 18 to 8…

This early-stage study tests an experimental drug called MOMA-341, taken as a pill, for people with advanced solid tumors that have specific genetic features (MSI-H or dMMR). The study includes up to 132 adults whose cancer has not responded to prior treatments. The main goal is …

This study tests a new drug called GI-108 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is designed to help the immune system fight cancer. The trial has two parts: first, finding a safe dose, and then seeing if it shrinks tumors. About 7…

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This study tests a new drug called GI-101, either alone or with pembrolizumab or lenvatinib, in people with advanced solid tumors (cancers that have spread). The goal is to see if it is safe and works against the cancer. About 317 adults with certain cancers like lung, kidney, or…

This early-stage trial tests a combination of two drugs, niraparib and irinotecan, in people with advanced solid tumors that have mutations in DNA repair genes like BRCA, ATM, or PALB2. The main goal is to find a safe dose and understand side effects. About 24 adults with cancers…

This early-phase study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various solid cancers…

This early-phase study tests a new drug, CLSP-1025, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have a specific genetic change called p53 R175H and a certain immune type (HLA-A*02:01). The goal is to find a safe dose and see if the drug can …

This study tests an experimental drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments w…

This study tests a new oral drug called ART6043, which blocks a DNA repair protein in cancer cells. It is given alone or with olaparib to adults with advanced or metastatic solid tumors that have not responded to other treatments. The goal is to see if it is safe and can shrink o…

This study tests whether two drugs, tucatinib and T-DM1, can control HER2-positive solid tumors that have spread to the brain. About 30 adults with this condition will receive the combination and be monitored for side effects and tumor response. The goal is to find a better treat…

This study is for children and young adults with advanced or spreading solid tumors. It tests a new drug called repotrectinib combined with two chemotherapy drugs (irinotecan and temozolomide). The goal is to find the safest dose and see if the combination helps shrink tumors. Ab…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study tests a new drug called IPN60300 in adults with advanced solid tumors that have spread or not responded to standard treatments. The goal is to find the safest and most effective dose and to see if the drug can shrink tumors. All participants receive the drug by injecti…

This early-stage study tests an experimental drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 340 adults whose cancer ha…

This early-stage study is testing a new drug called SYN818 combined with olaparib in adults with advanced solid tumors (like ovarian or breast cancer) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 110 part…

This early-stage study tests a new drug, ASD141, in 21 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug moves through the body and whether…

This study tests a new drug called DS-3939a in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose, and to see if the drug can shrink tumors. About 540 adults will take part across multiple centers.

This study tests a new drug called AGX101 in people with advanced solid tumors that have not responded to standard treatments. The drug is given through a vein and aims to shrink or control tumors. The main goals are to find the safest dose and understand side effects. About 80 p…

This early-phase study tests a new experimental drug called JZP898, given alone or with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This early-phase study tests whether a new drug, CHS-114, combined with the immunotherapy toripalimab (and possibly other standard treatments) is safe and can shrink tumors in people with advanced or metastatic solid tumors. About 154 adults whose prior treatments have stopped wo…

This study tests a new drug called zidesamtinib (NVL-520) in people with advanced lung cancer or other solid tumors that have a specific genetic change (ROS1-positive). The goal is to find the best dose and see how well it shrinks tumors. About 359 adults will take part. The drug…

This early-phase study tests a new drug called BGB-B455 in people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find the safest dose and understand side effects. About 90 participants will join, and the study has two parts: f…

This early-phase study tests a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 101 people with certain cancer…

This study tests a new drug called NVL-655 in people with advanced ALK-positive lung cancer and other solid tumors. The goal is to find the best dose and see how well it shrinks tumors. About 840 participants will take the pill daily, and researchers will monitor side effects and…

This study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to standard immunotherapy. The goal is to find a safe and effective dose that can slow or stop tumor growth. Participants receive the drug and are mo…

This early-phase study tests a new drug called ADU-1805, alone or with another cancer drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the drug moves through the body. About 130 p…

This early-phase study tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors. It is a first-in-human trial, so the main focus is on …

This early-stage study tests an experimental pill called NVL-330 in about 200 adults with advanced lung cancer that has a specific change in the HER2 gene. The main goals are to find a safe dose and see if the drug can shrink tumors or slow the cancer. Participants must have trie…

This early-phase trial tests a new drug called XB628 in about 75 people whose advanced solid tumors have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to check safety and fi…

This study tests whether combining two drugs, afatinib and pemigatinib, is safe and can shrink tumors in people with advanced solid cancers that have certain genetic changes (FGFR alterations). About 70 adults whose standard treatments have stopped working will take part. The mai…

This early-stage study tests a new drug, BGB-B2033, alone or with other medicines, in people with advanced liver, stomach, lung, or yolk sac cancers that have spread. The main goals are to check safety and find the right dose. About 140 participants will take part.

This study tests a new imaging agent (89Zr-DFO-REGN5054) that may show where immune cells are active in tumors. About 50 adults with advanced solid cancers will receive the agent and a PET scan, along with the immunotherapy cemiplimab. The goal is to check safety and see if the s…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps immune cells attack…

This study tests if a tretinoin cream can help reduce the acne-like rash that some cancer patients get from their treatment. About 25 adults with advanced solid tumors will apply the cream to one side of their face and a placebo to the other. Researchers will compare the rash sev…